James Van Der Beek, the acclaimed actor known for his diverse roles in television and film, has taken on a critical mission with Guardant Health to raise awareness about groundbreaking advancements in colorectal cancer screening for adults 45 and older. As of late July 2025, this powerful partnership aims to help millions overcome hesitancy around cancer screening by promoting the latest FDA-approved blood test designed for easier and more accessible detection of this deadly disease.
Colorectal cancer, the second most lethal cancer in the United States, claims more than 50,000 lives each year. Shockingly, 75% of deaths occur among patients who were never screened—often because traditional methods like colonoscopy are seen as unpleasant or inconvenient. Recognizing this gap, Guardant Health has introduced the Shield blood test, offering a simple blood-draw alternative for adults at average risk beginning at age 45.
James Van Der Beek is now sharing his own experience with colorectal cancer, hoping to encourage others to avoid the pain and risk he has endured. “I was 46 years old, in great physical shape, and had no idea I was living with stage 3 colorectal cancer,” explained Van Der Beek. “It’s the second most deadly cancer, but the most curable when caught in its early stages, making screening crucial. I was relieved to learn about Guardant’s Shield blood test because it’s a more pleasant and convenient way to get screened, especially for those who’ve been hesitating. If you’re 45 or older, make sure you talk to your doctor about screening guidelines and your options.”
What Sets Shield Apart?
Shield is the first blood test to be approved by the FDA specifically for colorectal cancer screening among average-risk adults 45 and up. Its appeal is clear:
- Simple blood draw: No prep, sedation, or dietary changes—a doctor’s visit can provide the sample.
- Early detection: Catching cancer early often leads to much higher survival rates.
- Convenience: For those who delay or refuse conventional screening, Shield eliminates most barriers.
In July 2025, Shield received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services, confirming its innovative value and ensuring reimbursement for Medicare patients at $1,495 during its initial pricing period. This inclusion means more Americans can access life-saving screening without cost as a barrier.
The Impact: Addressing a Critical Health Gap
Regular screening can prevent around 70% of colorectal cancer deaths, yet more than one in three adults aged 50 to 75 are not screened as recommended. Shield joins other screening options—like colonoscopies (every 10 years) or stool-based tests (annually or every three years)—but aims to boost participation from those who avoid traditional methods.
Key facts:
- Over 1 in 23 men and 1 in 25 women in the U.S. will be diagnosed with colorectal cancer in their lifetime.
- Early-stage colorectal cancer has a five-year survival rate of over 90%.
- Shield is covered by Medicare and is expected to see wide adoption as physicians and patients seek less invasive screening solutions.
Why This Partnership Matters
Van Der Beek’s courage in sharing his diagnosis and treatment journey is already making an impact. By putting a familiar face to the message and using his platform, he’s helping shatter taboos and push for open conversations about screening.
Dr. AmirAli Talasaz, Guardant Health co-CEO, noted, “We are grateful to James for the work he has done to raise awareness with his personal story that shows the importance of screening and early detection.”
At a Glance: Shield vs. Traditional Screening
| Screening Method | Preparation | Invasiveness | Frequency | Accessibility |
|---|---|---|---|---|
| Colonoscopy | Yes | High | Every 10 years | MD/Lab setting |
| Stool-based Test | Minimal | Low | Annual or 3 years | At-home/lab |
| Shield Blood Test | None | None | Ask doctor (varies) | Routine clinic |
Take Action
Guardant Health and James Van Der Beek are urging all adults 45 and up to discuss colorectal cancer screening options with their healthcare providers. Don’t let fear or discomfort keep you from potentially life-saving detection. Shield is making it easier than ever to get screened and protect your future.
Have thoughts or questions about this breakthrough in cancer screening? Let us know in the comments below—your feedback helps drive awareness and saves lives.